MTVA MetaVia Inc.

NASDAQ
$1.66

MetaVia Inc. (MTVA) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.94 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +16.1% since its last earnings release on August 6, 2026.

MetaVia Missed Consensus Estimates
Thursday, August 6, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.94)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.63

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About MetaVia Inc.

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.